Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.74 |
| ▸ | LNPEP | Q9UIQ6 | 7/20 | 0.51 |
| ▸ | ERAP2 | Q6P179 | 4/20 | 0.51 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.47 |
| ▸ | MAP1LC3A | Q9H492 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | REN | P00797 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP3 | P08254 | 1/20 | 0.43 |
| ▸ | MMP7 | P09237 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1206766 | 0.88 | LNPEP (0.59) | AAK1LNPEPERAP2CTSSCTSK | |
| SCHEMBL1391452 | 0.86 | AAK1 (0.53) | AAK1LNPEPERAP2HDAC1 | |
| SCHEMBL1391454 | 0.86 | AAK1 (0.53) | AAK1LNPEPERAP2HDAC1 | |
| SCHEMBL19328184 | 0.85 | AAK1 (1.00) | AAK1MAP1LC3BMAP1LC3ACTSLCTSB | |
| SCHEMBL17515973 | 0.85 | AAK1 (1.00) | AAK1MAP1LC3BMAP1LC3ACTSLCTSB | |
| SCHEMBL30022338 | 0.82 | AAK1 (0.73) | AAK1MAP1LC3BMAP1LC3ACTSLCTSB | |
| SCHEMBL12433335 | 0.76 | AAK1 (0.54) | AAK1LNPEPERAP2 | |
| SCHEMBL9490468 | 0.75 | AAK1 (0.62) | AAK1MAP1LC3BMAP1LC3ACTSLCTSB | |
| SCHEMBL1479155 | 0.75 | AAK1 (0.60) | AAK1CTSLCTSSHDAC1 | |
| SCHEMBL1479930 | 0.75 | AAK1 (0.78) | AAK1CTSBCTSSCTSKHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6903128-B2 | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases | PFIZER INC (US) | 2005-06-07 | — | — | US | disclosed |
| US-20040102496-A1 | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases | DUPLANTIER ALLEN J (US) | 2004-05-27 | — | — | US | disclosed |
| US-6668527-B2 | Antiinflamamtory agents; autoimmune disease | PFIZER INC. | 2003-12-30 | — | — | US | disclosed |
| US-6667331-B2 | For example 3-(2-(1-(2-(3-Methoxy-4-(3-o-tolyl-ureido)-phenyl)-acetylamino )-3-methyl-butyl)-4,5-dihydro-oxazol-5-yl)-2-methyl-propionic acid | PFIZER INC | 2003-12-23 | — | — | US | disclosed |
| US-20030100585-A1 | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases | DUPLANTIER ALLEN J (US) | 2003-05-29 | — | — | US | disclosed |
| US-20030004196-A1 | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases | DUPLANTIER ALLEN J (US) | 2003-01-02 | — | — | US | disclosed |
| EP-1244656-A1 | NON-PEPTIDYL INHIBITORS OF VLA-4 DEPENDENT CELL BINDING USEFUL IN TREATING INFLAMMATORY, AUTOIMMUNE, AND RESPIRATORY DISEASES | Pfizer Products Inc. (US) | 2002-10-02 | — | — | EP | disclosed |
| US-20020049236-A1 | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases | PFIZER INC. | 2002-04-25 | — | — | US | disclosed |
| WO-2001051487-A1 | NON-PEPTIDYL INHIBITORS OF VLA-4 DEPENDENT CELL BINDING USEFUL IN TREATING INFLAMMATORY, AUTOIMMUNE, AND RESPIRATORY DISEASES | PFIZER PRODUCTS INC. (US) | 2001-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004196-A1 | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases | VCAM1, SELPLG, CCR10 | AAK1 3783/4885LNPEP 889/4885ERAP2 3583/4885 |
| US-20040102496-A1 | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases | VCAM1, SELPLG, VSIG8 | AAK1 3790/4885LNPEP 937/4885ERAP2 3667/4885 |
| US-20020049236-A1 | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases | VCAM1, CCR10, SELPLG | AAK1 3548/4885LNPEP 960/4885ERAP2 3842/4885 |
| US-20030100585-A1 | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases | VCAM1, SELP, SELPLG | AAK1 2778/4885LNPEP 175/4885ERAP2 1890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.